Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00330798 · ClinicalTrials.gov registry record · Phase 4
A Comparison of Topical Nepafenac to Placebo in Corneal Epithelial Healing Times and Postoperative Pain Relief
A Phase 4 study of Photorefractive Keratectomy, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT00330798 is a Phase 4 study of Photorefractive Keratectomy that has completed, run by Alcon Research. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00330798, a Phase 4 study of Photorefractive Keratectomy, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare healing times and subjective pain level responses of nepafenac to placebo after photo refractive keratomileusis (PRK) surgery.
Conditions Studied
Interventions
- DRUG nepafenac 0.1%
- OTHER ketorolac 0.4%
Study Locations (1)
Texas
- Lackland Air Force Base - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2006-02 |
| Est. Completion | 2006-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00330798
The ClinicalTrials.gov registry entry for NCT00330798 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Photorefractive Keratectomy appearing as the primary indexed condition, and to 2 interventions - of which nepafenac 0.1% is the first listed.
NCT00330798 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00330798 about?
NCT00330798 is a clinical study titled "A Comparison of Topical Nepafenac to Placebo in Corneal Epithelial Healing Times and Postoperative Pain Relief". The purpose of this study is to compare healing times and subjective pain level responses of nepafenac to placebo after photo refractive keratomileusis (PRK) surgery.
What is the current status of trial NCT00330798?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2006-02. Estimated completion is 2006-06.
What conditions does trial NCT00330798 study?
This clinical trial studies the following conditions: Photorefractive Keratectomy.
What interventions are being tested in trial NCT00330798?
The interventions under investigation include: nepafenac 0.1% (DRUG), ketorolac 0.4% (OTHER).
Who is sponsoring clinical trial NCT00330798?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00330798 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Photorefractive Keratectomy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.